| 摘要 |
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
|
| 申请人 |
AHMED GULZAR;BRESLIN HENRY J.;BURKE JASON;CURRY MATTHEW A.;DIEBOLD JAMES L.;DORSEY BRUCE D.;DUGAN BENJAMIN J.;FENG DAMING;GINGRICH DIANE E.;GUO TAO;LEARN KEITH S.;LISKO JOSEPH;LIU RONG-QIANG;MESAROS EUGEN F.;MILKIEWICZ KAREN L.;OTT GREGORY R.;THEROFF JAY P.;THIEU THO;TRIPATHY RABINDRANATH;UNDERINER THEODORE L.;WELLS GREGORY J.;ZIFICSAK CRAIG A.;CEPHALON, INC. |
发明人 |
AHMED GULZAR;BRESLIN HENRY J.;BURKE JASON;CURRY MATTHEW A.;DIEBOLD JAMES L.;DORSEY BRUCE D.;DUGAN BENJAMIN J.;FENG DAMING;GINGRICH DIANE E.;GUO TAO;LEARN KEITH S.;LISKO JOSEPH;LIU RONG-QIANG;MESAROS EUGEN F.;MILKIEWICZ KAREN L.;OTT GREGORY R.;THEROFF JAY P.;THIEU THO;TRIPATHY RABINDRANATH;UNDERINER THEODORE L.;WELLS GREGORY J.;ZIFICSAK CRAIG A. |
